

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

Juan G. Ripoll^{1*}, MD, Sidna M. Tullidge-Scheitel^{2*}, MD, MPH, Anthony A. Stephenson¹, MD, Shane Ford¹, BS, Marsha L. Pike³, APRN, CNS, DNP, Ellen K. Gorman¹, BS, Sara N. Hanson⁴, DO, MPH, Justin E. Juskewitch⁵, MD, PhD, Alex J. Miller¹, BS, Solomiia Zaremba¹, MD, Erik A. Ovrom¹, BA, Raymund R. Razonable⁶, MD, Ravindra Ganesh⁷, MBBS, MD, Ryan T. Hurt⁷, MD, PhD, Erin N. Fischer³, MS, RN, Amber N. Derr⁸, MBA, Michele R. Eberle⁹, Jennifer J. Larsen⁸, MSN, RN, Christina M. Carney¹⁰, APRN, CNP, DNP, Elitza S. Theel⁵, PhD, Sameer A. Parikh¹¹, MBBS, Neil E. Kay^{11,12}, MD, Michael J. Joyner^{1,13†}, MD, and Jonathon W. Senefeld^{1,13,14‡}, PhD

AFFILIATIONS

- 1 | Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
- 2 | Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota
- 3 | Department of Nursing, Mayo Clinic, Rochester, Minnesota
- 4 | Department of Family Medicine, Mayo Clinic Health Care System, Mankato, Minnesota
- 5 | Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- 6 | Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota
- 7 | Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota
- 8 | Division of Hematology and Infusion Therapy, Rochester, Minnesota, USA
- 9 | Mayo Clinic Health System Northwest Wisconsin, Eau Claire, Wisconsin, USA
- 10 | Mayo Clinic Health System, Red Wing, Minnesota,
- 11 | Division of Hematology, Mayo Clinic, Rochester, Minnesota
- 12 | Department of Immunology, Mayo Clinic, Rochester, Minnesota
- 13 | Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota
- 14 | Department of Health and Kinesiology, University of Illinois at Urbana-Champaign, Urbana, Illinois

✉Correspondence:

Jonathon W. Senefeld, PhD, Department of Health and Kinesiology
University of Illinois Urbana-Champaign | 906 S Goodwin | Urbana, Illinois 61801
senefeld@illinois.edu | 217-300-7991

* Dr. Ripoll and Dr. Tullidge-Scheitel contributed equally as first authors to the work of the study and manuscript.

† Drs. Joyner and Senefeld contributed equally as senior authors to the work of the study and manuscript.

1 **ABSTRACT**

2 Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with
3 COVID-19 are generally preventable among healthy vaccine recipients, patients with
4 immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at
5 high risk of infection with SARS-CoV-2 and hospitalization. Additionally, monoclonal antibody
6 therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped
7 neutralization. In this context, there is interest in understanding the clinical benefit associated
8 with COVID-19 convalescent plasma collected from persons who have been both naturally
9 infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 (“vax-plasma”). Thus, we report
10 the clinical outcome of 386 immunocompromised outpatients who were diagnosed with
11 COVID-19 and who received contemporary COVID-19 specific therapeutics (standard of care
12 group) and a subgroup who also received concomitant treatment with very high titer COVID-19
13 convalescent plasma (vax-plasma group) with a specific focus on hospitalization rates. The
14 overall hospitalization rate was 2.2% (5 of 225 patients) in the vax-plasma group and 6.2% (10
15 of 161 patients) in the standard of care group, which corresponded to a relative risk reduction
16 of 65% ($P=0.046$). Evidence of efficacy in nonvaccinated patients cannot be inferred from these
17 data because 94% (361 of 386 patients) of patients were vaccinated. In vaccinated patients with
18 immunosuppression and COVID-19, the addition of vax-plasma or very high titer COVID-19
19 convalescent plasma to COVID-19 specific therapies reduced the risk of disease progression
20 leading to hospitalization.

21 **IMPORTANCE**

22 As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged which evade available
23 anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However,
24 high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its
25 broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386
26 immunocompromised outpatients who were treated with COVID-19 specific therapeutics and a
27 subgroup also treated with vaccine-boosted convalescent plasma. We found that
28 administration of vaccine-boosted convalescent plasma was associated with a significantly
29 decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our
30 data add to the contemporary data providing evidence to support the clinical utility of high-titer
31 convalescent plasma as antibody replacement therapy in immunocompromised patients.

32 Introduction

33 Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with
34 COVID-19 are generally preventable among healthy vaccine recipients, patients with
35 immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at
36 high risk of infection with SARS-CoV-2 and hospitalization.^{1,2} Passive antibody therapy, via
37 monoclonal antibody therapy or COVID-19 convalescent plasma, has been widely used to treat
38 COVID-19, particularly among patients with immunosuppression.³⁻⁵ For example, in the
39 outpatient setting, therapeutic use of neutralizing antispikes monoclonal antibody has been
40 associated with decreases in the incidence of COVID-19-related disease progression and
41 hospitalization.⁶ However, monoclonal antibody therapy is limited by the emergence of novel
42 SARS-CoV-2 variants that have serially escaped neutralization.^{7,8} Thus, although monoclonal
43 antibody therapy as a cornerstone of COVID-19 treatment, at the time of this writing, there are
44 no US FDA approved monoclonal antibodies for the treatment or prevention of SARS-CoV-2
45 infection.⁶ However, high-titer COVID-19 convalescent plasma continues to be effective against
46 SARS-CoV-2 variants of concern (VOCs) because of its broad-spectrum immunomodulatory
47 properties and ability to neutralize multiple SARS-CoV-2 variants.^{9,10} Although COVID-19
48 convalescent plasma is authorized for therapeutic use among patients with
49 immunosuppression in the US and recommended by some organizations^{11,12}, its use remains
50 controversial.⁴

51 COVID-19 convalescent plasma collected from persons who have been both naturally infected
52 with SARS-CoV-2 and vaccinated against SARS-CoV-2 (herein referred to as “vax-plasma” and
53 also known as vaccine-boosted convalescent plasma) is particularly high titer, typically
54 containing 10 to 100 times higher anti-SARS-CoV-2 antibody titers than standard COVID-19
55 convalescent plasma.¹³⁻¹⁷ To further our understanding of the clinical impact associated with
56 vax-plasma, we report the clinical outcome of 386 immunocompromised outpatients who were
57 diagnosed with COVID-19 and treated with contemporary COVID-19 specific therapeutics
58 (standard of care group) and a subgroup who also received treatment with vax-plasma or high-
59 titer COVID-19 convalescent plasma and (vax-plasma group) with a specific focus on
60 hospitalization rates.

61 Study design

62 This large, observational cohort study included data from a single health system (Mayo Clinic)
63 and represented data from multiple health care sites across Minnesota and Wisconsin from 1
64 December 2022 to 1 December 2023. Immunocompromised patients with active COVID-19
65 infection, confirmed by SARS-CoV-2-specific reverse transcription polymerase chain reaction,
66 were eligible to receive vax-plasma. The Mayo Clinic Institutional Review Board determined

67 that this study met the criteria for exemption. Informed consent was waived. Only Mayo Clinic
68 patients with research authorization were included.

69 As previously described¹⁷, eligible vax-plasma donors included individuals who had a confirmed
70 diagnosis of COVID-19 and had received at least one dose of a SARS-CoV-2 vaccine. All donors
71 experienced mild to moderate symptoms and met the national blood donor selection criteria.
72 Vax-plasma was collected at least 10 days and up to 6 months after the complete resolution of
73 COVID-19 symptomatology. Antibody titers of vax-plasma units met the minimum threshold
74 required by the US FDA for high titer anti-SARS-CoV-2 antibodies, but precise antibody titers
75 were not evaluated. However, numerous reports indicate that vax-plasma is uniformly
76 extremely high titer with neutralizing activity against many SARS-CoV-2 variants^{10,13,18}. The
77 treatment schedule of vax-plasma transfusions was not standardized. Patients received the
78 number of vax-plasma units deemed appropriate for each patient by their clinicians (range, 1 to
79 7 units).

80 The primary outcome was COVID-19–related hospitalization within 28 days after transfusion,
81 assessed as the cumulative incidence in the vax-plasma group compared to the standard of care
82 group who declined treatment vax-plasma. The decision to hospitalize patients was at the
83 discretion of local clinicians. Continuous measures were compared between the treatment
84 groups (vax-plasma group vs. standard of care group) using the two-sample t-test, whereas
85 categorical measures were compared using the χ^2 test or Fisher exact test, as appropriate.
86 Reported p-values are two-sided and adjusted for multiplicity, as appropriate; and the
87 interpretation of findings was based on $p < 0.05$.

88 Results and discussion

89 Three-hundred eighty-six immunocompromised patients were offered standard of care
90 treatments (e.g., remdesivir, nirmatrelvir or molnupiravir) and were also offered to be treated
91 with vax-plasma. Of those patients, 58% agreed to treatment with vax-plasma (225 of 386
92 patients; vax-plasma group) and 42% (161 of 386 patients) received standard of care
93 treatments alone without vax-plasma (standard of care group). Key demographic and clinical
94 characteristics of the study population are provided in **Table 1**, stratified into the two treatment
95 groups. Overall, the median age of all patients was 66 years (range: 2 to 96 years), 45% were
96 female (175 of 386 patients), and 94% (361 of 386 patients) were vaccinated against SARS-CoV-
97 2.

98 Compared to patients in the standard of care group, patients in the vax-plasma group were
99 more likely to be female ($P=0.038$), more likely to have received anti-CD20 monoclonal therapy
100 ($P=0.028$), and more likely to have received previous COVID-19 antiviral treatments ($P<0.001$).
101 Other key differences between the groups are noted in **Table 1**.

102 Patients had COVID-19 symptoms for a median of 5 days (range, 1 to 46 days) before receiving
103 vax-plasma, and the median number of units transfused per patient was 1 (range, 1 to 7 units of
104 vax-plasma). Most patients (73%, 281 of 386 patients) agreed to receive concomitant COVID-
105 19–specific treatments, and patients in the vax-plasma group were more likely to have received
106 COVID-19 specific treatments (88%, 198 of 225 patients) compared to the standard of care
107 group (52%, 83 of 161 patients; $P<0.001$). COVID-19 specific treatments included remdesivir
108 (65% of patients who accepted vax-plasma and 32% of those who declined vax-plasma),
109 nirmatrelvir and ritonavir (PAXLOVID™) (28% in the vax-plasma group and 20% in the standard
110 of care group), and/or molnupiravir (1% in the vax-plasma group and 4% in the standard of care
111 group).

112 No major adverse effects were recorded among patients transfused with vax-plasma. The
113 overall 28 day-hospital admission rate was 2.2% (5 of 225 patients) in vax-plasma group and
114 6.2% (10 of 161 patients) in standard of care group ($P=0.046$).

115 In this large, non-randomized cohort study involving outpatients with recent SARS-CoV-2
116 infection, the concomitant administration of high-titer COVID-19 convalescent plasma in
117 addition to standard of care therapeutics was associated with a decreased incidence of
118 hospitalization. Our observations are consistent with those of previous trials of antibody-based
119 therapies —administration of sufficient pathogen-specific antibodies via COVID-19 convalescent
120 plasma leads to a reduced risk of disease progression, COVID-19-related hospitalization, and
121 COVID-19-related death in immunocompromised patients in both outpatient and inpatient
122 settings.^{5,19} Collectively, contemporary clinical data provide evidence to support the utility of
123 high-titer convalescent plasma including vax-plasma as antibody replacement therapy in
124 immunocompromised patients.^{17,20,21}

125 There is consensus that the primary mechanism of action of vax-plasma is through viral
126 neutralization¹⁹—a finding established among humans early during the COVID-19 pandemic²²
127 and supported by several preclinical models including mice,^{23,24} hamsters,²⁵ and macaques.²⁶
128 Because the neutralizing capacity of vax-plasma can evolve with emerging variants, issues
129 related to escape by new variants that have time limited the efficacy of monoclonal antibodies
130 can potentially be avoided. Additionally, sero-surveys of blood donors show a high prevalence
131 of hybrid immunity in the population suggesting that very high titer vax-plasma is potentially
132 available at a scale sufficient to treat immunocompromised patients.²⁷ Thus, there is an
133 emerging picture of utility for vax-plasma therapy in immunocompromised patients with SARS-
134 CoV-2 infection that could benefit from further evaluation via carefully matched, larger real
135 world data sets. Importantly, any prospective studies will need to consider the experimental
136 design and ethical issues associated with potentially limiting a safe antibody therapy in

137 immunocompromised patients unable to generate an adequate endogenous antibody response
138 to infection.

139 Our study faced several contextual challenges associated with clinical research during a
140 pandemic and limitations associated with the design of the study. First, the interpretation of
141 these results is limited by the open-label and non-randomized design. In this framework, the
142 vax-plasma group had higher rates of anti-CD20 monoclonal therapy, antiviral COVID-19-
143 specific therapeutics, and vaccination against SARS-CoV-2. Importantly, treatment with anti-
144 CD20 monoclonal therapy among people who are immunosuppressed is associated with the
145 lowest likelihood to produce SARS-CoV-2 antibodies after one or more doses of COVID-19
146 vaccines.^{16,28} Thus, the effects of vax-plasma *per se* may not be definitively inferred. Second, the
147 overall incidence of hospitalization was very low (3.8%, 15 of 386 patients), likely due in part to
148 the very high number of patients who were vaccinated against SARS-CoV-2 and because most
149 patients received standard of care COVID-19-specific therapeutics. In this context, the low
150 incidence of the primary outcome (COVID-19–related hospitalization) limited the potential for
151 definitive subgroup analyses according to coexisting immunosuppressive conditions or other
152 putative confounding variables. Third, SARS-CoV-2 serology of vax-plasma units or patient
153 samples was not systematically performed.

154 Despite the enumerated limitations of this study, our data provides evidence that transfusion of
155 vax-plasma effectively transfers COVID-19-neutralizing antibodies to patients with
156 immunosuppression and reduces the risk of COVID-19-related hospitalization. Vax-plasma
157 appears to be an effective therapeutic throughout the clinical course of COVID-19 among
158 immunocompromised patients from outpatients to inpatients with protracted COVID-19. For
159 future pandemics, the use of therapeutic plasma with antibody levels in the upper deciles
160 should be considered, particularly among immunocompromised patients.

Acknowledgments

We thank the dedicated members of the Mayo Clinic Blood Donor Center for their rigorous efforts necessary to make this program possible. We also thank the donors who survived COVID-19 for providing vaccine-boosted COVID-19 convalescent plasma. Additionally, we thank Diana Zicklin Berrent and Chaim Lebovits for their progressive and passionate patient advocacy and support.

This work was supported by United Health Group and Mayo Clinic.

Authorship Contributions

Study conception and design: J.G.R., S.M.T-S, M.J.J., and J.W.S. Acquisition, analysis, or interpretation of data: J.G.R., S.M.T-S, A.A.S., S.F., M.L.P., E.K.G., A.J.M., S.Z., E.A.O., and J.W.S. Drafting of the manuscript: J.G.R., S.M.T-S, M.J.J., and J.W.S. Administrative, technical, or material support: S.N.H., J.E.J., R.R.R., R.G., R.T.H., E.N.F., A.N.D., M.R.E., J.J.L., C.M.C., E.S.T., S.A.P., and N.E.K. All authors contributed to revising the manuscript, and all authors approved the final version of the manuscript.

Disclosure of Conflicts of interest

The authors declare no conflict of interest.

Data Availability

Datasets generated during this study may be available from corresponding authors on reasonable request. Requestors may be required to sign a data use agreement. Data sharing must be compliant with all applicable Mayo Clinic policies and those of the Mayo Clinic Institutional Review Board.

ORCID

Juan G. Ripoll	https://orcid.org/0000-0003-4908-9774
Shane Ford	https://orcid.org/0000-0003-2776-9023
Ellen K. Gorman	https://orcid.org/0000-0003-2989-547X
Justin E. Juskewitch	https://orcid.org/0000-0002-7868-2852
Alexander J. Miller	https://orcid.org/0009-0006-2814-5561
Solomiia Zaremba	https://orcid.org/0009-0006-3030-7232
Erik A. Ovrom	https://orcid.org/0000-0002-5661-0698
Raymund R. Razonable	https://orcid.org/0000-0001-5248-0227
Ravindra Ganesh	https://orcid.org/0000-0002-6877-1712
Elitza S. Theel	https://orcid.org/0000-0002-6886-2294
Sameer A. Parikh	https://orcid.org/0000-0002-3221-7314
Neil E. Kay	https://orcid.org/0000-0002-5951-5055
Michael J. Joyner	https://orcid.org/0000-0002-7135-7643
Jonathon W. Senefeld	https://orcid.org/0000-0001-8116-3538

References

1. Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. *Nat Rev Clin Oncol*. 2022;19(6):385-401.
2. Ribas A, Dhodapkar MV, Campbell KM, et al. How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. *Blood Cancer Discov*. 2021;2(6):562-567.
3. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. *Nature Reviews Immunology*. 2021;21(6):382-393.
4. Shoham S, Batista C, Ben Amor Y, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. *eClinicalMedicine*. 2023;59:101965.
5. Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2023;6(1):e2250647.
6. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *Lancet Infect Dis*. 2022;22(11):e311-e326.
7. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. *Int J Mol Sci*. 2021;23(1).
8. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med*. 2022;28(3):490-495.
9. Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. *Transfusion*. 2021;61(8):2503-2511.
10. Li M, Beck EJ, Laeyendecker O, et al. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. *Blood Adv*. 2022;6(12):3678-3683.
11. Estcourt LJ, Cohn CS, Pagano MB, et al. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. *Ann Intern Med*. 2022;175(9):1310-1321.
12. Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). *Leukemia*. 2022;36(6):1467-1480.
13. Schmidt F, Weisblum Y, Rutkowska M, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature*. 2021;600(7889):512-516.
14. Hueso T, Poudoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. *Blood*. 2020;136(20):2290-2295.
15. Thompson MA, Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncol*. 2021;7(8):1167-1175.
16. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell*. 2021;39(8):1031-1033.

17. Ripoll JG, Gorman EK, Juskewitch JE, et al. Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. *Blood Adv.* 2022;6(23):5951-5955.
18. Callaway E. COVID super-immunity: one of the pandemic's great puzzles. *Nature.* 2021;598(7881):393-394.
19. Casadevall A, Joyner MJ, Pirofski LA, et al. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. *Expert Rev Respir Med.* 2023;17(5):381-395.
20. Senefeld JW, Joyner MJ. SARS-CoV-2 Antibody Replacement Therapy for Immunocompromised Patients. *Clin Infect Dis.* 2023.
21. Upasani V, Townsend K, Wu MY, et al. Commercial immunoglobulin products contain neutralising antibodies against SARS-CoV-2 spike protein. *Clin Infect Dis.* 2023.
22. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A.* 2020;117(17):9490-9496.
23. Golden JW, Zeng X, Cline CR, et al. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. *J Gen Virol.* 2021;102(5).
24. Zheng J, Wong LR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. *Nature.* 2021;589(7843):603-607.
25. Haagmans BL, Noack D, Okba NMA, et al. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. *J Infect Dis.* 2021;223(12):2020-2028.
26. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature.* 2021;590(7847):630-634.
27. Focosi D, Meschi S, Coen S, et al. Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure. *Vox Sang.* 2023.
28. Pearce FA, Lim SH, Bythell M, et al. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. *Lancet Rheumatol.* 2023;5(8):e461-e473.

Table 1. Characteristics of 386 immunocompromised outpatients who were diagnosed with COVID-19 and received standard of care COVID-19 therapeutics with or without vax-plasma.

	Vax-plasma, N = 225	SOC, N = 161	P value
Demographic information			
Age, median (range), years	66 (2-93)	64 (20-96)	0.468
Females/males, n	112/113	63/98	0.038
Height, median (range), cm	172.5 (85.3-195.0)	173.0 (146.2-197.4)	0.440
Weight, median (range), kg	82.7 (12.4-176.0)	81.5 (44.6-210.0)	0.691
Body Mass Index, median (range), kg·m ⁻²	28.1 (17.0-54.1)	27.6 (18.2-63.7)	0.952
Hematological malignancies, n (%)			
Multiple Myeloma	30 (13)	38 (24)	0.009
Chronic lymphocytic leukemia	43 (19)	20 (12)	0.080
Diffuse large B-cell lymphoma	20 (9)	23 (14)	0.097
Follicular lymphoma	15 (7)	4 (2)	0.061
Other malignancy ^a	57 (25)	45 (28)	0.331
Other immunosuppressive conditions, n (%)			
Multiple sclerosis	25 (11)	6 (4)	0.008
Solid organ transplant ^b	13 (6)	13 (8)	0.375
Common variable immune deficiency	3 (1)	5 (3)	0.228
Granulomatosis with Polyangiitis	5 (2)	4 (2)	0.866
Other immunosuppressive conditions ^c	17 (8)	9 (6)	0.447
Active immunosuppressive treatment, n (%)			
Anti-CD20 therapy	78 (35)	39 (24)	0.028
Anti-CD38 therapy	15 (7)	11 (7)	0.949
Bruton tyrosine kinase inhibitors	22 (10)	11 (7)	0.307
Previous COVID-19-specific treatments, n (%)			
Remdesivir	198 (88)	83 (52)	<0.001
Remdesivir	146 (65)	52 (32)	<0.001
Paxlovid	62 (28)	33 (20)	0.112
Molnupiravir	3 (1)	6 (4)	0.124
Vaccinated against SARS-CoV-2, n (%)	214 (95)	147 (91)	0.134
Number of SARS-CoV-2 vaccines^d, mean (SD), n	3.8 (1.6)	3.7 (1.2)	0.504
Units of vax-plasma, median (range), n	1 (1-7)	--	--
Time to treatment, median (range), days	5 (1-46)	--	--
Hospital admission, n (%)	5 (2.2)	10 (6.2)	0.046

Footnotes

Note that hematological malignancies and other immunosuppressive conditions are not mutually exclusive.

^aOther malignancies included acute lymphoblastic leukemia (ALL, n = 5); acute myeloid leukemia (AML, n = 7); anaplastic large cell lymphoma (N = 1); angioimmunoblastic T-cell Lymphoma (n = 1); chronic lymphoproliferative disorder of natural killer cells (CLPD-NK, n = 1); chronic myeloid leukemia (CML, n = 8); chronic myelomonocytic leukemia (CMML, n = 1); cutaneous B-cell lymphoma (n = 1); Dermatomyositis (n = 1); duodenal adenocarcinoma (n = 1); gastroesophageal junction adenocarcinoma (n = 1); Hairy Cell Leukemia (n = 1); hodgkin lymphoma (HL, n = 11); large granular lymphocytic leukemia (n = 1); lung adenocarcinoma (n = 3); MALT Lymphoma (n = 2); mantle cell lymphoma (MCL, n = 8); marginal zone lymphoma (MZL, n = 12); Metastatic Carcinoid Tumor (n = 1); Metastatic Melanoma (n = 1); monoclonal gammopathy of undetermined significance (MGUS, n = 5); myelodysplastic syndrome (MDS, n = 8); Myelofibrosis (n = 1); Polycythemia Vera (n = 2); Prolymphocytic Leukemia (n = 1); Testicular Cancer (n = 1); non-Hodgkin lymphoma (n = 1), and small lymphocytic lymphoma (n = 1); Waldenstrom macroglobulinemia (WM, n = 16).

^bSolid organ transplants included: kidney (n = 3); heart (n = 1); kidney and pancreas (n = 4); lung(s) (n = 11); lung and heart (n = 1); kidney and liver (n = 2); kidney and heart (n = 3); and heart, liver, and kidney (n = 1).

^cOther immunosuppressive conditions included: autoimmune lymphoproliferative syndrome (ALPS, n = 1); Amyloidosis (n = 2); ANCA Vasculitis (n = 2); autoimmune myositis (n = 2); HIV (n = 2); Immune Thrombocytopenic Purpura (ITP, n = 1); membranous nephropathy (MN, n = 1); minimal change disease (n = 1); Neuromyelitis Optica (n = 1); Rheumatoid Arthritis (RA, n = 6); Stiff-Person Syndrome (SPS, n = 1); systemic lupus erythematosus (SLE, n = 3); thrombotic thrombocytopenic purpura (TTP, n = 1); undifferentiated primary immunodeficiency (n = 1); and a constellation of comorbidities (seizure disorder, previous stroke, ventricular septal defect, prolonged QT interval, right bundle-branch block, congestive heart failure, chronic obstructive pulmonary disease; n = 1).

^dThe mean number of SARS-CoV-2 vaccines was calculated among people who have been vaccinated against SARS-CoV-2, including 214 patients in the vax-plasma group and 147 patients in the standard of care (SOC) group.